Biden has been dishing out so much government aid lately that some states don’t even know what to do with it.
The gargantuan $1.9 trillion American Rescue Plan Act (ARPA) is chock-full of funding for every conceivable sector. Recipients have been given a general idea of where the money can be used, but overall it looks like each state will have the final say.
Until more information is available, a few cities have even started asking the public for advice. ARPA’s core goal is to help mitigate the effects of the coronavirus pandemic, so aid could come in almost any form.
As of now, the lion’s share of the ARPA funding is earmarked for one of the fastest-growing sectors on the planet.
It shouldn’t come as a huge shock that these select companies are reaping the benefits of their hard work.
After all, when the coronavirus hit, they stepped up and met the challenge head-on.
Now they’re being rewarded with a well-deserved payout…
The Most Important Industry on Earth
The COVID-19 pandemic was an enlightening time, for lack of a better word. It was an unplanned, unprecedented experiment that produced some truly incredible data.
The economy took an absolute nosedive as entire countries went into lockdown. Service industries and small businesses were almost eradicated. Those that survived were trapped in a permanent state of fight or flight as they desperately tried to stay afloat.
Practically overnight, the future of the economy became dependent on one crucial industry: biotechnology.
And until an effective vaccine was developed, the world was left at a standstill.
Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
Crafting an experimental vaccine using bleeding-edge mRNA technology during one of the worst humanitarian crises in recent memory sounded like a tall order. The moral of the story here is that biotech is hands-down one of the most valuable industries we have.
And considering the huge amount of federal funding heading its way, I’d say Biden agrees wholeheartedly.
A Massive Payout Is Looming for Investors
Many of you might be wondering what all this means for the biotech sector itself. Aside from the billions in ARPA funding, the entire playing field is vastly different than it was in pre-pandemic days.
Relaxed regulations meant that the FDA approved 53 new medical treatments in 2020 alone. Groundbreaking therapies for previously untreatable diseases like Duchenne muscular dystrophy, progeria, and some rare cancers have all been discovered as a direct result of COVID research.
Combined with record-breaking private funding and the potential for massive 1,000% stock gains, the biotech industry found a golden opportunity disguised as a global tragedy.
Investors were suddenly forced to completely rethink their approach to biotech investing.
The old days of waiting for regularly scheduled trial results or FDA decisions were long gone. Identifying bona fide catalysts became a full-time job, and weeding through hundreds of expedited reports per week simply wasn’t feasible in the long run.
But after months of trial and error, our team of analysts perfected a system that is closer to foolproof than anything else I’ve ever encountered in my trading career. I sometimes can’t help but wonder if they haven’t just found an inside man at the FDA. I strongly recommend you check this out.
Dubbed Project Greenlight, this shockingly simple methodology can hand you up to four triple-digit winners in the biotech sector every single month.
Click here to find all the details so you can put this battle-tested strategy to work for you and start raking in historic profits.
To your wealth, Luke Sweeney Luke’s technical know-how combined with an insatiable scientific curiosity has helped uncover some of our most promising leads in the tech sector. He has a knack for breaking down complicated scientific concepts into an easy-to-digest format, while still keeping a sharp focus on the core information. His role at Angel is simple: transform piles of obscure data into profitable investment leads. When following our recommendations, rest assured that a truly exhaustive amount of research goes on behind the scenes..
Contributor, Energy and Capital
Check us out on YouTube!
